Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 6/20 | 0.70 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.70 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.70 |
| ▸ | DRD2 | P14416 | 3/20 | 0.57 |
| ▸ | DRD1 | P21728 | 2/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.56 |
| ▸ | DRD3 | P35462 | 2/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
| ▸ | DRD5 | P21918 | 1/20 | 0.51 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.50 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.50 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.50 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.50 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.50 |
| ▸ | MIF | P14174 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11593827 | 0.86 | CHRM2 (0.59) | OPRK1OPRM1OPRD1DRD2DRD1 | |
| SCHEMBL3380877 | 0.85 | OPRK1 (0.62) | OPRK1OPRM1OPRD1DRD2DRD1 | |
| SCHEMBL8459688 | 0.85 | OPRK1 (0.62) | OPRK1OPRM1OPRD1DRD2DRD1 | |
| SCHEMBL9504204 | 0.85 | OPRK1 (0.62) | OPRK1OPRM1OPRD1DRD2DRD1 | |
| SCHEMBL9579004 | 0.85 | OPRM1 (0.50) | OPRK1OPRM1OPRD1TAAR1GABRA1 | |
| SCHEMBL266149 | 0.85 | TAAR1 (0.58) | OPRK1OPRM1OPRD1DRD2DRD1 | |
| Ethoxycarbonyl Group SCHEMBL26106421 | 0.83 | OPRM1 (0.52) | OPRK1OPRM1OPRD1DRD2DRD1 | |
| SCHEMBL24261197 | 0.83 | OPRK1 (0.55) | OPRK1OPRM1OPRD1DRD2DRD1 | |
| SCHEMBL18122727 | 0.83 | OPRK1 (1.00) | OPRK1OPRM1OPRD1DRD2DRD1 | |
| Phenol SCHEMBL28856311 | 0.82 | OPRK1 (0.57) | OPRK1OPRM1OPRD1DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122037020-A | Supported catalyst, preparation method thereof and application thereof in olefin polymerization | 中国石油化工股份有限公司 | 2026-05-15 | — | — | CN | claimed |
| CN-122037020-A | Supported catalyst, preparation method thereof and application thereof in olefin polymerization | 中国石油化工股份有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-11254686-B1 | Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor | CORVUS PHARMACEUTICALS, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| CN-112679635-A | Preparation method of supported metallocene catalyst and catalyst prepared by same | 中国石油化工股份有限公司 | 2021-04-20 | — | — | CN | disclosed |
| WO-2019046784-A1 | COMPOUNDS AND METHODS FOR MODULATING ADENOSINE A2B RECEPTOR AND ADENOSINE A2A RECEPTOR | CORVUS PHARMACEUTICALS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| US-20150299125-A1 | PRODRUG BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-10-22 | — | — | US | disclosed |
| US-8623867-B2 | Cyclic amine BACE-1 inhibitors having a benzamide substituent | MERCK SHARP & DOHME CORP. (US) | 2014-01-07 | — | — | US | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| EP-1117002-B1 | Negative-working resist composition | FUJIFILM CORP (JP) | 2010-04-14 | — | — | EP | disclosed |
| US-7514520-B2 | Process for producing phosphonitrilic acid ester | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2009-04-07 | — | — | US | disclosed |
| US-20080161288-A1 | COMPOUNDS | PFIZER INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080091050-A1 | Process For Producing Phosphonitrilic Acid Ester | ASAHI KASEI CHEMICAL CORPORATION (JP) | 2008-04-17 | — | — | US | disclosed |
| US-7342124-B2 | Synthetic techniques and intermediates for polyhydroxy dienyl lactones and mimics thereof | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2008-03-11 | — | — | US | disclosed |
| US-7342124-B2 | Synthetic techniques and intermediates for polyhydroxy dienyl lactones and mimics thereof | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2008-03-11 | — | — | US | disclosed |
| US-20070060739-A1 | Process for producing phosphonitrilic acid ester | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | NR0B1, GRK7, NR5A2 | OPRK1 201/4885OPRM1 1146/4885OPRD1 567/4885 |
| US-20080091050-A1 | Process For Producing Phosphonitrilic Acid Ester | PHOSPHO1, GNPAT, SELENOI | OPRK1 4764/4885OPRM1 4486/4885OPRD1 4618/4885 |
| US-11254686-B1 | Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor | ADORA2A, ADORA2B, ADORA3 | OPRK1 294/4885OPRM1 272/4885OPRD1 406/4885 |
| US-20150299125-A1 | PRODRUG BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS | SYK, IRAK1, BTK | OPRK1 857/4885OPRM1 1871/4885OPRD1 1305/4885 |
| US-20080161288-A1 | COMPOUNDS | ADRB2, ADRB1, ADRA2C | OPRK1 88/4885OPRM1 327/4885OPRD1 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.